Century Therapeutics (IPSC) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($228.6 million vs $211.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | SCTX |
|---|---|---|
| Share price | $1.17 | $12.07 |
| Market cap | $211.56M | $228.58M |
| 1-day change | -11.74% | -8.70% |
| YTD return | +17.09% | — |
| 1-year return | +137.76% | — |
| 5-year return | -93.23% | — |
| EPS (TTM) | $-0.64 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.16M | — |
| Revenue growth (YoY) | +1556.76% | — |
| Net income (latest FY) | $-9.58M | — |
| Operating margin | -15.82% | — |
| Net margin | -8.78% | — |
| 52-week high | $3.04 | $39.60 |
| 52-week low | $0.48 | $12.00 |
| Distance from 52-week high | -61.68% | -69.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +307.73% | +372.25% |
| Average volume | 759.69K | 403.27K |
| Shares outstanding | 181.60M | 18.94M |
| Employees | 78 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
IPSC vs SCTX FAQ
Which is bigger, Century Therapeutics or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $211.56M for Century Therapeutics (IPSC).
Are Century Therapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.